In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: A comparative study in Bcrp1 -/- mice

Pharmaceutical Research

Volumn 27, Issue 10, 2010, Pages 2098-2105

  Merino, Gracia ^a   Perez, Miriam ^a   Real, Rebeca ^a   Egido, Estefania ^a   Prieto, Julio G ^a   Alvarez, Ana I ^a  

^a UNIVERSITY OF LEÓN   (Spain)

Author keywords

BCRP ABCG2; Bcrp1 ; isoflavones; MDCKII cells; nitrofurantoin

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DAIDZEIN; GENISTEIN; NITROFURANTOIN;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG MILK LEVEL; DRUG TRANSPORT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LACTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ANTI-INFECTIVE AGENTS, URINARY; ATP-BINDING CASSETTE TRANSPORTERS; BILE; BIOLOGICAL TRANSPORT; CELL CULTURE TECHNIQUES; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FEMALE; GENISTEIN; HUMANS; ISOFLAVONES; LACTATION; MICE; MICE, KNOCKOUT; MILK; NEOPLASM PROTEINS; NITROFURANTOIN;

EID: 77957336580     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0208-5     Document Type: Article

References (45)

1. T Ishikawa H Nakagawa 2009 Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics J Exp Ther Oncol. 8 1 5 24 19827267
2. RW Robey KK To O Polgar M Dohse P Fetsch M Dean SE Bates 2009 ABCG2: a perspective Adv. Drug Deliv. Rev. 61 3 13 10.1016/j.addr.2008.11.003 19135109
3. LJA Hardwick S Velamakanni HW van Veen 2007 The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2) Brit. J. Pharmacol. 151 163 174 10.1038/sj.bjp.0707218 (Pubitemid 46763043)
4. Robey RW, Polgar O, Deeken J, To KKW, Bates SE. Breast Cancer Resistance Protein. In: You G, Morris ME, editors. Drug Transporters: molecular characterization and role in drug disposition. New Jersey: Wiley; 2007. p. 319-58.
5. AE Van Herwaarden E Wagenaar B Karnekamp G Merino JW Jonker AH Schinkel 2006 Breast cancer resistance protein (Bcrp1/Abcg2) reduce systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk Carcinogenesis 27 123 130 10.1093/carcin/bgi176 16000399 (Pubitemid 43025252)
6. JW Jonker G Merino S Musters AE van Herwaarden E Bolscher E Wagenaar E Mesman TC Dale AH Schinkel 2005 The breast cancer resistance protein (BCRP/ABCG2) concentrates drugs and carcinogenic xenotoxins into milk Nat. Med 11 127 129 10.1038/nm1186 15685169 (Pubitemid 40321346)
7. G Merino AI Alvarez MM Pulido AJ Molina AH Schinkel JG Prieto 2006 Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion Drug Metab. Dispos 34 690 695 10.1124/dmd.105.008219 16434544
8. AE van Herwaarden E Wagenaar G Merino JW Jonker H Rosing JH Beijnen AH Schinkel 2007 Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk Mol. Cell. Biol. 27 1247 1253 10.1128/MCB.01621-06 17145775 (Pubitemid 46239808)
9. G Merino JW Jonker E Wagenaar AE van Herwaarden AH Schinkel 2005 The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic Nitrofurantoin Mol. Pharmacol 67 1758 1764 10.1124/mol.104.010439 15709111 (Pubitemid 40594177)
10. L Wang M Leggas M Goswami PE Empey PJ McNamara 2008 N-(4-[2-(1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9, 10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk Drug Metab. Dispos. 36 2591 2596 10.1124/dmd.108.021980 18799806
11. Y Zhang L Zhou JD Unadkat Q Mao 2009 Effect of pregnancy on nitrofurantoin disposition in mice J. Pharm. Sci. 98 4306 4315 10.1002/jps.21698 19422048
12. Y Zhang H Wang JD Unadkat Q Mao 2007 Bcrp1 Limits Fetal Distribution of Nitrofurantoin in the Pregnant Mouse Drug Metab. Dispos 35 2154 2158 10.1124/dmd.107.018044 17785426 (Pubitemid 350146200)
13. G Merino AE van Herwaarden E Wagenaar JW Jonker AH Schinkel 2005 Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver Mol. Pharmacol 67 1765 1771 10.1124/mol.105.011080 15722455 (Pubitemid 40594178)
14. A Jacobs U Wegewitz C Sommerfeld R Grossklaus A Lampen 2009 Efficacy of isoflavones in relieving vasomotor menopausal symptoms - A systematic review Mol. Nutr. Food Res. 53 1084 1097 10.1002/mnfr.200800552 19653225
15. M Hu 2007 Commentary: Bioavailability of Flavonoids and Polyphenols: Call to Arms Mol. Pharm. 4 803 806 10.1021/mp7001363 18052085
16. ME Morris S Zhang 2006 Flavonoid-drug interactions: effects of flavonoids on ABC transporters Life Sci 78 2116 2130 10.1016/j.lfs.2005.12.003 16455109
17. AI Alvarez R Real M Perez G Mendoza JG Prieto G Merino 2010 Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response J. Pharm. Sci. 99 598 617 19544374
18. X Wang ME Morris 2007 Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2 Drug Metab. Dispos 35 268 274 10.1124/dmd.106.011684 17093006 (Pubitemid 46148740)
19. S Zhang X Yang ME Morris 2004 Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport Pharm. Res 21 1263 1273 10.1023/B:PHAM.0000033015.84146.4c 15290869 (Pubitemid 38954213)
20. S Zhang X Wang K Sagawa ME Morris 2005 Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice Drug Metab. Dispos. 33 341 348 10.1124/dmd.104.002501 15608138 (Pubitemid 40279933)
21. A Kawase Y Matsumoto M Hadano Y Ishii M Iwaki 2009 Differential effects of chrysin on nitrofurantoin pharmacokinetics mediated by intestinal breast cancer resistance protein in rats and mice J. Pharm. Pharm. Sci. 12 150 163 19732493
22. M Perez R Real G Mendoza G Merino JG Prieto AI Alvarez 2009 Milk secretion of nitrofurantoin, as a specific BCRP/ABCG2 substrate, in assaf sheep: modulation by isoflavones J. Vet. Pharmacol. Ther. 32 498 502 10.1111/j.1365-2885.2008.01050.x 19754918
23. JD Allen A van Loevezijn JM Lakhai M van der Valk O van Tellingen G Reid JH Schellens GJ Koomen AH Schinkel 2002 Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C Mol. Cancer. Ther. 1 417 425 12477054
24. M Perez AG Blazquez R Real G Mendoza JG Prieto G Merino AI Alvarez 2009 In vitro and in vivo interaction of moxidectin with BCRP/ABCG2 Chem. Biol. Interact. 180 106 112 10.1016/j.cbi.2009.02.009 19428349
25. Y Imai S Tsukahara S Asada Y Sugimoto 2004 Phytoestrogens/flavonoids reverse breastcancer resistance protein/ABCG2-mediated multidrug resistance Cancer Res 64 4346 4352 10.1158/0008-5472.CAN-04-0078 15205350 (Pubitemid 38802442)
26. SW Wang J Chen X Jia VH Tam M Hu 2006 Disposition of flavonoids via enteric recycling: structural effects and lack of correlations between in vitro and in situ metabolic properties Drug Metab. Dispos. 34 1837 1848 10.1124/dmd.106.009910 16882763 (Pubitemid 44771711)
27. S Zhang K Sagawa RD Arnold E Tseng X Wang ME Morris 2010 Interactions between the flavonoid biochanin A and P-glycoprotein substrates in rats: In vitro and in vivo J Pharm Sci. 99 430 441 10.1002/jps.21827
28. U Muenster B Grieshop K Ickenroth MJ Gnoth 2008 Characterization of substrates and inhibitors for the in vitro assessment of BCRP mediated drug-drug interactions Pharm Res. 25 10 2320 2326 10.1007/s11095-008-9632-1 18523872
29. U Telang Y Ji ME Morris 2009 ABC transporters and isothiocyanates: potential for pharmacokinetic diet-drug interactions Biopharm Drug Dispos 30 7 335 344 10.1002/bdd.668
30. JD Allen RF Brinkhuis J Wijnholds AH Schinkel 1999 The mouse Bcrp1/Mxr/Abcp gene:amplification and overexpression in cell lines selected for resistance totopotecan, mitoxantrone, or doxorubicin Cancer Res. 59 4237 4241 10485464
31. H Xu KH Kulkarni R Singh Z Yang SW Wang VH Tam M Hu 2009 Disposition of Naringenin via Glucuronidation Pathway Is Affected by Compensating Efflux Transporters of Hydrophilic Glucuronides Mol. Pharm. 6 1703 1715 10.1021/mp900013d 19736994
32. MM Pulido AJ Molina G Merino JG Prieto AI Alvarez 2006 Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): Influence of flavonoids and role in milk secretion in sheep J. Vet. Pharmacol. Ther 29 279 287 10.1111/j.1365-2885.2006.00744.x 16846465 (Pubitemid 43995435)
33. J Enokizono H Kusuhara Y Sugiyama 2007 Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens Mol. Pharmacol. 72 4 967 975 10.1124/mol.107.034751 17644650 (Pubitemid 47481419)
34. L Zhang Z Zuo G Lin 2007 Intestinal and hepatic glucuronidation of flavonoids Mol Pharm. 4 6 833 845 10.1021/mp700077z 17979245
35. S Zhou Y Hu B Zhang Z Teng H Gan Z Yang Q Wang M Huan Q Mei 2008 Dose-dependent absorption, metabolism, and excretion of genistein in rats J. Agric. Food Chem 56 18 8354 8359 10.1021/jf801051d 18710250
36. YJ Moon K Sagawa K Frederick S Zhang ME Morris 2006 Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats AAPS J. 8 3 E433 442 10.1208/aapsj080351 17025260 (Pubitemid 44096604)
37. T Kishida M Nagamoto Y Ohtsu M Watakabe D Ohshima K Nashiki T Mizushige T Izumi A Obata K Ebihara 2004 Lack of an inducible effect of dietary soy isoflavones on the mRNA abundance of hepatic cytochrome P-450 isozymes in rats Biosci. Biotechnol Biochem. 68 3 508 515 10.1271/bbb.68.508 15056880 (Pubitemid 39251485)
38. G Williamson C Manach 2005 Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies Am. J. Clin. Nutr. 81 243S 255S 15640487
39. H Tamaki H Satoh S Hori H Ohtani Y Sawada 2010 Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids Drug Metab. Pharmacokinet. 25 170 179 10.2133/dmpk.25.170 20460823
40. S Bolca M Urpi-Sarda P Blondeel N Roche L Vanhaecke S Possemiers N Al-Maharik N Botting D De Keukeleire M Bracke A Heyerick C Manach H Depypere 2010 Disposition of soy isoflavones in normal human breast tissue Am. J. Clin. Nutr. 91 976 984 10.3945/ajcn.2009.28854 20164315
41. S Reagan-Shaw N Nihal M Ahmad 2007 Dose translation from animal to human studies revisited FASEB J 22 659 661 10.1096/fj.07-9574LSF 17942826
42. JE Andrade NC Twaddle WG Helferich DR Doerge 2010 Absolute bioavailability of isoflavones from soy protein isolate-containing food in female BALB/c mice J. Agric. Food Chem. 58 4529 4536 10.1021/jf9039843 20225898
43. KD Setchell KD NM Brown P Desai L Zimmer-Nechemias BE Wolfe WT Brashear AS Kirschner A Cassidy JE Heubi 2001 Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements J. Nutr. 131 1362S 1375S 11285356
44. L Gu SE House RL Prior N Fang MJ Ronis TB Clarkson ME Wilson TM Badger 2006 Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women J. Nutr 136 1215 1221 16614407
45. MA Cimafranca J Davila GC Ekman RN Andrews SL Neese J Peretz KA Woodling WG Helferich J Sarkar JA Flaws SL Schantz DR Doerge PS Cooke 2010 Acute and chronic effects of oral genistein administration in neonatal mice Biol. Reprod. 83 114 121 10.1095/biolreprod.109.080549 20357267